The analysis focused on prediabetes
The longer SURMOUNT-1 analysis involved 1,032 participants who had both obesity and prediabetes. They received assigned tirzepatide or placebo for 176 weeks, followed by 17 weeks off treatment. Diabetes was diagnosed in 1.3% of the combined tirzepatide groups and 13.3% of the placebo group during treatment. At the later follow-up, the figures were 2.4% and 13.7%. This is strong evidence about progression during a defined study, not proof of permanent prevention.[1]
Prediabetes is a laboratory-defined discussion
NIDDK explains that prediabetes involves glucose levels above normal but below the diabetes range, and that clinicians use tests such as A1C or fasting glucose to assess it. Symptoms or a family history alone do not establish the diagnosis. Before applying trial headlines to yourself, ask what your actual test results show and when they should be reassessed.[2]
A useful absolute-risk calculation
The during-treatment proportions differ by 12 percentage points. For illustration, in two hypothetical groups of 1,000 with the reported study proportions, that corresponds to about 13 diagnoses versus 133. It does not mean 120 diagnoses would be prevented in any group of 1,000 readers: the starting risk, eligibility and length of observation have to match. The arithmetic clarifies scale without creating an individualized benefit estimate.
Why “after stopping” needs a time limit
The off-treatment observation lasted 17 weeks. That is not a lifelong follow-up and cannot tell us whether an effect persists indefinitely after withdrawal. It also does not determine the best treatment duration for one person. A reader should distinguish delaying a diagnosis over the observed period from eliminating future risk. Ask the clinician how long-term follow-up would continue whether treatment is maintained, changed or stopped.[1] For the separate weight-maintenance question, read weight regain after stopping GLP-1 treatment.
Set goals beyond a single headline
At an appointment, ask which outcomes matter in your case: glucose measurements, weight-related symptoms, other risk factors or medication tolerability. Request the schedule for reviewing them. A broad goal such as “prevent diabetes” becomes more actionable when linked to documented tests and follow-up responsibilities. Do not compare one person’s short-term weight response with a three-year diabetes outcome as though they measure the same thing.
Compare like time windows
A one-year diagnosis rate from another study and the nearly three-year treatment result here do not measure the same exposure to risk. Even if both headlines use the word prevention, first align the starting population and follow-up. A small percentage over a short period can coexist with a larger percentage over a longer period. For a personal discussion, ask when testing will happen again and who will review it. Ongoing measurement is more concrete than treating one reassuring laboratory result as the end of the question.
Keep coverage and medical evidence separate
A published trial is not an insurance authorization, and the study title does not itself establish a product’s approved indication. Ask the prescribing clinician which product and indication are being considered, then ask the insurer for the applicable rules. If comparing care services, record who handles documentation and what fees continue while a coverage decision is pending. This avoids treating promising research as a guarantee of affordable access. Our prior-authorization guide helps separate those steps.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
Prices and terms can change. Confirm your specific offer directly with the provider.